Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population

被引:0
|
作者
Bozina, N
Granic, P
Lalic, Z
Tramisak, I
Lovric, M
Stavljenic-Rukavina, A
机构
[1] Univ Zagreb, Ctr Hosp, Univ Inst Lab Diag, Zagreb 10000, Croatia
[2] Sch Med, Zagreb, Croatia
关键词
alleles; Croatia; cytochrome P450 enzyme system; genotype; phenotype; polymorphism (genetics);
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To determine the prevalence of most common mutations of cytochrome P450 (CYP), ie, allelic variants of CYP2C9, CYP2C19, and CYP2D6, and to predict genotype frequency in the Croatian population. Methods. CYP genotype was determined in 200 non-related Croatian citizens. DNA isolated from blood samples was used for the analysis of the most common allelic variants of CYP2C9, CYP2C19, and CYP2D6 by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Results. For 200 subjects genotyped for CYP2C9, the allele frequencies of CYP2C9*1 (wt), CYP2C9*2, and CYP2C9*3 were 0.74 0.165 and 0.095, respectively. Among them, 3.5% of subjects were predicted to be poor metabolizers. For CYP2C19, the most frequent alleles were CYP2C19*1 and CYP2C19*2, with frequencies of 0.85 and 0.15 respectively; 3% of subjects were predicted to be poor metabolizers. For CYP2D6, the most frequent alleles were CYP2D6*1 (frequency 0.765), CYP2D62* (0.04), CYP2D6*3 (0.0275), CYP2D6*4 (0.14), CYP2D6*5 (0.01), and CYP2D6*6 (0.015). Out of these, 3% were predicted to be poor metabolizers, and 4% were predicted to be ultra-rapid metabolizers. Conclusion. The prevalence of allelic variants and predicted genotypes in the Croatian population is in accordance with the other European populations, and it can be interpolated between the values for mid-European and Mediterranean populations.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 50 条
  • [31] Identification of the Effects of Pathogenic Genetic Variations of Human CYP2C9 and CYP2D6: An In Silico Approach
    Avsar, Orcun
    CYTOLOGY AND GENETICS, 2024, 58 (02) : 152 - 166
  • [32] Identification of the effects of pathogenic genetic variations of human CYP2C9 and CYP2D6: an in silico approach
    Avsar, Orcun
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2024, 43 (04) : 356 - 376
  • [33] Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: in vitro and in silico studies
    Joshi, Kaishiv
    Kaur, Satbir
    Kumar, Rakesh
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (19) : 9389 - 9402
  • [34] Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
    Herrlin, K
    Yasui-Furukori, N
    Tybring, G
    Widén, J
    Gustafsson, LL
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (04) : 415 - 421
  • [35] Distribution of CYP2C9*13 allele in the Chinese Han and the long-range haplotype containing CYP2C9*13 and CYP2C19*2
    Si, Dayong
    Wang, Juan
    Zhang, Yifan
    Zhong, Dafang
    Zhou, Hui
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (06) : 342 - 345
  • [36] Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
    Swen, J. J.
    van der Straaten, T.
    Wessels, J. A. M.
    Bouvy, M. L.
    Vlassak, E. E. W.
    Assendelft, W. J. J.
    Guchelaar, H. -J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (04) : 363 - 370
  • [37] No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
    Vangsted, Annette J.
    Soeby, Karen
    Klausen, Tobias W.
    Abildgaard, Niels
    Andersen, Niels F.
    Gimsing, Peter
    Gregersen, Henrik
    Vogel, Ulla
    Werge, Thomas
    Rasmussen, Henrik B.
    BMC CANCER, 2010, 10
  • [38] Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients
    Fan, Xinghua
    Zhang, Hong
    Wen, Zhipeng
    Zheng, Xiaoli
    Yang, Yi
    Yang, Jihong
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (04) : 152 - 158
  • [39] Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice
    Jurgens, G.
    Jacobsen, C. B.
    Rasmussen, H. B.
    Werge, T.
    Nordentoft, M.
    Andersen, S. E.
    ACTA PSYCHIATRICA SCANDINAVICA, 2012, 125 (03) : 228 - 237
  • [40] Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations
    Abdelhedi, Rania
    Bouayed, Nouha Abdelmoula
    Alfadhli, Suad
    Abid, Leila
    Rebai, Ahmed
    Kharrat, Najla
    JOURNAL OF GENETICS, 2015, 94 (04) : 765 - 770